These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 1293056)
1. Intracellular bactericidal activity of fosfomycin against staphylococci: a comparison with other antibiotics. Trautmann M; Meincke C; Vogt K; Ruhnke M; Lajous-Petter AM Infection; 1992; 20(6):350-4. PubMed ID: 1293056 [TBL] [Abstract][Full Text] [Related]
2. In vitro activity of fosfomycin combined with rifampin, pefloxacin and imipenem against staphylococci: a study by the time-kill curve method. Quentin C; Saivin S; Lafferriere C; Noury P; Bebear C Drugs Exp Clin Res; 1987; 13(4):219-24. PubMed ID: 3476291 [TBL] [Abstract][Full Text] [Related]
3. The microbiological efficacy of the combination of fosfomycin and vancomycin against clinically relevant staphylococci. Gatermann S; Schulz E; Marre R Infection; 1989; 17(1):35-7. PubMed ID: 2921087 [TBL] [Abstract][Full Text] [Related]
4. Comparison of fosfomycin and teicoplanin in serum bactericidal activity against staphylococci. Vogt K; Rauhut A; Trautmann M; Hahn H Arzneimittelforschung; 1995 Aug; 45(8):894-7. PubMed ID: 7575756 [TBL] [Abstract][Full Text] [Related]
5. Antibacterial activity of teicoplanin and vancomycin in combination with rifampicin, fusidic acid or fosfomycin against staphylococci on vein catheters. Simon VC; Simon M Scand J Infect Dis Suppl; 1990; 72():14-9. PubMed ID: 2151061 [TBL] [Abstract][Full Text] [Related]
6. Influence of different peritoneal dialysis fluids on the in vitro activity of fosfomycin against Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa. Kussmann M; Hauer S; Pichler P; Reznicek G; Burgmann H; Poeppl W; Zeitlinger M; Wiesholzer M Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1091-1098. PubMed ID: 29546637 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of fosfomycin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy. Pistella E; Falcone M; Baiocchi P; Pompeo ME; Pierciaccante A; Penni A; Venditti M Infez Med; 2005 Jun; 13(2):97-102. PubMed ID: 16220029 [TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility of Staphylococcus aureus and Staphylococcus epidermidis isolated from prosthetic joint infections. Molina-Manso D; del Prado G; Ortiz-Pérez A; Manrubia-Cobo M; Gómez-Barrena E; Cordero-Ampuero J; Esteban J J Antibiot (Tokyo); 2012 Oct; 65(10):505-8. PubMed ID: 22854340 [TBL] [Abstract][Full Text] [Related]
9. In vitro activity of fosfomycin in combination with various antistaphylococcal substances. Grif K; Dierich MP; Pfaller K; Miglioli PA; Allerberger F J Antimicrob Chemother; 2001 Aug; 48(2):209-17. PubMed ID: 11481290 [TBL] [Abstract][Full Text] [Related]
10. Bactericidal effect of ofloxacin alone and combined with fosfomycin or vancomycin against Staphylococcus aureus in vitro and in sera from volunteers. Weber P; Boussougant Y; Ichou F; Dutoit C; Carbon C J Antimicrob Chemother; 1987 Dec; 20(6):839-47. PubMed ID: 3481627 [TBL] [Abstract][Full Text] [Related]
11. Variable tolerance of a clinical isolate of Staphylococcus epidermidis from an infected hydrocephalus shunt for several beta-lactam antibiotics, vancomycin and fosfomycin. Traub WH Chemotherapy; 1981; 27(6):432-43. PubMed ID: 7297172 [TBL] [Abstract][Full Text] [Related]
12. [Are we being threatened by multiresistant strains of Staphylococcus aureus?]. Aepfelbacher M MMW Fortschr Med; 2005 Jan; 147(4):33-5, 37. PubMed ID: 15745339 [TBL] [Abstract][Full Text] [Related]
13. [In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis]. Soriano A; Jurado A; Marco F; Almela M; Ortega M; Mensa J Rev Esp Quimioter; 2005 Jun; 18(2):168-72. PubMed ID: 16130039 [TBL] [Abstract][Full Text] [Related]
14. Antistaphylococcal activity of teicoplanin in Riyadh, Saudi Arabia. Shibl AM; Ishag AH; Durgham SM APMIS Suppl; 1988; 3():68-70. PubMed ID: 2972301 [TBL] [Abstract][Full Text] [Related]
15. Telavancin: in vitro activity against staphylococci in a biofilm model. Gander S; Kinnaird A; Finch R J Antimicrob Chemother; 2005 Aug; 56(2):337-43. PubMed ID: 15972312 [TBL] [Abstract][Full Text] [Related]
16. Enhancement of the susceptibility of Staphylococcus aureus to phagocytosis after treatment with fosfomycin compared with other antimicrobial agents. Pérez Fernández P; Herrera I; Martínez P; Gómez-Lus ML; Prieto J Chemotherapy; 1995; 41(1):45-9. PubMed ID: 7875021 [TBL] [Abstract][Full Text] [Related]
17. [In vitro study of the effects of an imipenem-fosfomycin combination against clinical strains of Staphylococcus]. Fosse T; David MF; Duluc F Pathol Biol (Paris); 1986 Dec; 34(10):1055-9. PubMed ID: 3547260 [TBL] [Abstract][Full Text] [Related]
18. Chronic granulomatous disease: uptake and intracellular activity of fosfomycin in granulocytes. Höger PH; Seger RA; Schaad UB; Hitzig WH Pediatr Res; 1985 Jan; 19(1):38-44. PubMed ID: 3969311 [TBL] [Abstract][Full Text] [Related]
19. Effects of vancomycin, daptomycin, fosfomycin, tigecycline, and ceftriaxone on Staphylococcus epidermidis biofilms. Hajdu S; Lassnigg A; Graninger W; Hirschl AM; Presterl E J Orthop Res; 2009 Oct; 27(10):1361-5. PubMed ID: 19396814 [TBL] [Abstract][Full Text] [Related]
20. In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections. Fernández J; Greenwood-Quaintance KE; Patel R Diagn Microbiol Infect Dis; 2016 Aug; 85(4):449-51. PubMed ID: 27241369 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]